Stephen Hoge - 14 Sep 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: President
Issuer ticker: MRNA
Reported as of: 14 Sep 2026
Net transaction value: -$11,691,420
SEC form: 4
Accepted by SEC: 16 Sep 2026, 16:48:33 UTC
Prior SEC filing: 03 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, as Attorney-in-Fact

Key filing fact

Stephen Hoge filed Form 4 for Moderna, Inc. (MRNA) on 16 Sep 2026.

Key facts

This page summarizes Stephen Hoge's Form 4 filing for Moderna, Inc. (MRNA).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 16:48.

Change

Previous filing in this sequence was filed on 03 Sep 2026.
Current net transaction value: -$11,691,420.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001760669 Primary reporting owner

Hoge Stephen

Relationship: President
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, as Attorney-in-Fact
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +76,453
Change %: +5.1%
Price: $12.21^*
Shares after: 1,566,152
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Sale

Transaction value: $5,807,574
Shares: -40,294
Change %: -2.6%
Price: $144.13
Shares after: 1,525,858
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F1, F2

MRNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +76,452
Change %: +5%
Price: $12.21^*
Shares after: 1,602,310
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1

MRNA transaction

Common Stock

Sale

Transaction value: $5,883,846
Shares: -40,281
Change %: -2.5%
Price: $146.07
Shares after: 1,562,029
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1, F3

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4,116
Date: 14 Sep 2026
Ownership: By Valhalla, LLC

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 151,933
Date: 14 Sep 2026
Ownership: By Trust
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -76,453
Change %: -17%
Price: $0.000000^*
Shares after: 382,262
Date: 14 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 76,453
Exercise price: $12.21
Footnotes: F1, F5

MRNA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -76,452
Change %: -20%
Price: $0.000000^*
Shares after: 305,810
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 76,452
Exercise price: $12.21
Footnotes: F1, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Footnote F4

These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F5

This option is fully vested and exercisable.